The market for cardiovascular drugs is the largest in terms of prescriptions and revenue. Kendle’s team of in-house physicians combines solid experience, expert knowledge and comprehensive service. We’ve already conducted more than 400 clinical projects in this area, involving one million patients. Our most recent success was in managing one of the world's largest global cardiovascular trials (nearly 8,000 patients, spanning 24 countries).
So, if yours is a cardiovascular study, look no further than Kendle.
Recently, Kendle took over the monitoring of a Chinese Phase IV cardiovascular study from another CRO who had monitored the trial for the previous 12 months. Prior to our involvement, the pharmaceutical sponsor had ranked China's performance as 24th out of the 40 participating countries. Under Kendle’s management, however, the ranking improved to ninth.